CN Patent

CN113966334A — (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙烷-1-胺的晶形及制备方法

Assigned to Cable Chart Pharmaceutical Co · Expires 2022-01-21 · 4y expired

What this patent protects

公开了化合物(I)的晶形： 其药学上可接受的盐以及任何前述物质的溶剂化物。还公开了包含它们的药物组合物、使用它们治疗与致癌KIT和PDGFRA改变相关的病症和病状的方法，以及制备化合物(I)及其晶形的方法。

USPTO Abstract

公开了化合物(I)的晶形： 其药学上可接受的盐以及任何前述物质的溶剂化物。还公开了包含它们的药物组合物、使用它们治疗与致癌KIT和PDGFRA改变相关的病症和病状的方法，以及制备化合物(I)及其晶形的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN113966334A
Jurisdiction
CN
Classification
—
Expires
2022-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Cable Chart Pharmaceutical Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.